KAPA
Kairos Pharma, LTD.Company Information
- Company Name
- Kairos Pharma, LTD.
- CIK
- CIK0001962011
- Category
- <br>Emerging growth company
- Ticker: Exchange
- KAPA: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KAPA
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-25
- Last sale
- —
- Shares purchased (TTM)
- 6,700
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 885,949
- Shares outstanding
- 21,420,479
- Ownership
- 4.14%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -25.96%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 3 | 4 | 4 | 6 | 3 | 4 | 1 | - | ||||||
| Cash | - | - | - | - | - | - | 1 | 3 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 3 | 4 | 5 | 7 | 5 | 6 | 4 | 5 | ||||||
| Deferred Costs | 1 | 1 | 1 | 1 | 2 | 2 | 1 | - | ||||||
| Intangible Assets Net Excluding Goodwill | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Noncurrent | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 0 | ||||||
| Assets | 4 | 6 | 7 | 8 | 7 | 8 | 6 | 5 | ||||||
Liabilities Current | ||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | ||||||
| Liabilities Current | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | ||||||
Stockholders Equity | ||||||||||||||
| Liabilities | - | - | - | - | - | - | 1 | 2 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 21 | 21 | 21 | 21 | 17 | 17 | 14 | 11 | ||||||
| Retained Earnings Accumulated Deficit | -17 | -16 | -14 | -13 | -11 | -10 | -9 | -8 | ||||||
| Stockholders Equity | 4 | 5 | 6 | 8 | 6 | 7 | 5 | 3 | ||||||
| Liabilities And Stockholders Equity | 4 | 6 | 7 | 8 | 7 | 8 | 6 | 5 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 21 | 21 | 21 | 21 | 18 | 16 | 14 | 13 | ||||||
| Shares Outstanding | 21 | 21 | 21 | 21 | 18 | 16 | 14 | 13 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKairos Pharma, LTD. (KAPA) — SEC Financial Statements & Analysis
Kairos Pharma, LTD. (KAPA) is a pharmaceutical preparations company, incorporated in DE. Kairos Pharma, LTD. trades on NYSE as: KAPA. Kairos Pharma, LTD. (KAPA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Kairos Pharma, LTD. carries a market cap of $57.58M, a P/E ratio of -9.92x, a P/B ratio of 13.74x, an enterprise value of $54.95M, and an EV/EBITDA multiple of -9.45x. On profitability, it posts a Return on Equity (ROE) of -113.96%, a Return on Assets (ROA) of -104.32%, and a Return on Invested Capital (ROIC) of -263.12%. Per share, it reports EPS of $-0.27, diluted EPS of $-0.27, free cash flow per share of $-0.19, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 9.80% year-over-year and EPS growth of -11.77% year-over-year. On the balance sheet, it maintains a current ratio of 11.98x, a quick ratio of 11.46x, working capital of $2.91M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, an interest coverage ratio of -265.96x, free cash flow of $-3.97M (TTM), and net debt of $-2.63M. Figures sourced from SEC EDGAR.
- Market Cap
- $57.58M
- P/E TTM
- -9.92x
- EPS TTM
- $-0.27
- P/B TTM
- 13.74x
- ROE TTM
- -113.96%
- ROA TTM
- -104.32%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-3.97M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Kairos Pharma, LTD. in?
Kairos Pharma, LTD. (KAPA) operates in the Pharmaceutical Preparations industry.
What exchange does KAPA trade on?
Kairos Pharma, LTD. (KAPA) trades on the NYSE.
Where is Kairos Pharma, LTD. incorporated?
Kairos Pharma, LTD. is incorporated in DE.
When was Kairos Pharma, LTD. (KAPA)'s most recent SEC filing?
Kairos Pharma, LTD. (KAPA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is KAPA's market cap?
Kairos Pharma, LTD. (KAPA) has a market capitalization of $57.58M as of 2026-06-30.
What is KAPA's EPS (earnings per share)?
Kairos Pharma, LTD. (KAPA)'s trailing twelve month EPS is $-0.27 as of 2026-06-30.
What is KAPA's ROE (return on equity)?
Kairos Pharma, LTD. (KAPA)'s trailing twelve month Return on Equity (ROE) is -113.96% as of 2026-06-30.
What is KAPA's ROA (return on assets)?
Kairos Pharma, LTD. (KAPA)'s trailing twelve month Return on Assets (ROA) is -104.32% as of 2026-06-30.
What is KAPA's ROIC (return on invested capital)?
Kairos Pharma, LTD. (KAPA)'s trailing twelve month Return on Invested Capital (ROIC) is -263.12% as of 2026-06-30.
What is KAPA's EV/EBITDA?
Kairos Pharma, LTD. (KAPA)'s trailing twelve month EV/EBITDA is -9.45x as of 2026-06-30.